Pinc PeptideThe girly peptide research blog

Growth hormone axis · Evidence tier B

GHRP-2 (pralmorelin)

pralmorelin · pralmorelin hydrochloride (JAN) · pralmorelin dihydrochloride (USAN) · KP-102 (Kaken’s development code) · GPA-748 (Wyeth-Ayerst code) · growth hormone-releasing peptide-2

GHRP-2 is a lab-made peptide that makes the body release growth hormone1. Japan approved it in 2004 as a one-dose test for growth hormone deficiency12. We found no trial of it for muscle gain or fat loss34.

Last reviewed · First published · 41 sources · 28 min read · By the Pinc Peptide editors

Illustration: a glass vial with a pink label reading GHRP-2
Illustration, not a real product: an empty glass vial (photo: Missouri Historical Society, public domain) with our label. See every vial.

Quick answers

What is it?
A lab-made chain of six amino acids that makes the body release growth hormone1. Japan approves it only as a one-dose test for growth hormone deficiency12. It is also sold online, often in blends, for muscle gain and fat loss45.
Does it work?
As a test, yes: it caught 85.3% of severe cases among 502 patients and ruled out 88.5% of the others2. For growth in short children, a nasal spray did no better than a dummy spray6. We found no trial of muscle gain or fat loss4.
Is it safe?
Before approval, about a third of 227 people in trials had side effects, such as a warm feeling; none was serious27. FDA cites serious reports, including deaths of critically ill study subjects, though a causal link is unproven8. Long-term safety is unknown4.
Is it legal?
Approved in Japan as a test, not in the US19. By our reading, US pharmacies may not make it101112. Prescription-only in Australia, and illegal to hold without one13. Canada has seized it as an unauthorized drug14. Banned in sport at all times1516.
What is in the vials?
Finnrick, which publishes lab tests of peptide samples, had no GHRP-2 results on 7 October 202617. US pharmacies recalled 30 sermorelin blends containing it from 2012 to 2019, all over sterility doubts18. Customs seizures in Denmark held look-alike copies with an extra amino acid19.

What it is

GHRP-2 (growth hormone-releasing peptide-2), also called pralmorelin, is a lab-made peptide of six amino acids. Three of them are mirror-image (D-) forms, including D-2-naphthylalanine, an unnatural building block not found in human proteins18. Like ghrelin, the ‘hunger hormone’, it switches on the ghrelin receptor (also called the growth hormone secretagogue receptor) and is thought to act mainly through the hypothalamus, so that the pituitary gland releases a burst of growth hormone (GH)17. After one dose into a vein, GH usually peaks within 15 to 60 minutes1. GHRP-2 also raises appetite and food intake2021, and it raises the stress hormones ACTH and cortisol and the hormone prolactin22. In Japan it is sold as GHRP KAKEN100 Injection, a one-dose test for growth hormone deficiency1.

GHRP-2 grew out of the work of C.Y. Bowers and colleagues at Tulane University in the US, who in 1977 found peptides that selectively released GH from the pituitary in laboratory experiments and in 1984 discovered GHRP-67. Kaken Pharmaceutical then began joint research with Bowers’s group and synthesized KP-102 (GHRP-2), which released GH more strongly7. It also carried the Wyeth-Ayerst code GPA-74823. After the receptor it acts on was described in 1996 and its natural partner, ghrelin, in 1999, GHRP-2 came to be seen as a ghrelin mimic7. Kaken developed it as a quicker test for severe GH deficiency: in its trials GH peaked about 30 minutes after a dose on average and within 60 minutes in everyone, vs about 60 to 120 minutes for older approved tests, so blood sampling could end at 60 minutes7. Japan approved it on 22 October 2004, and its international nonproprietary name is pralmorelin27.

Benefits: what the research shows

GHRP-2’s strongest evidence is as a diagnostic test. In 77 healthy adults and 58 patients whose insulin tolerance test, the standard test, showed severe GH deficiency, one 100 µg dose into a vein after an overnight fast produced a GH peak within 60 minutes in everyone. Peaks averaged 84.6 µg/L in healthy people and 1.36 µg/L in patients, and a cut-off of 15 µg/L matched the standard test’s 3 µg/L26. In Kaken’s post-marketing survey of 502 patients, 249 of them children, the test picked up 85.3% of the severe cases that doctors diagnosed with at least two other stimulation tests and correctly ruled out 88.5% of the rest2. In the confirmatory trial before approval, 23 of 50 people had side effects after GHRP-2, all mild, vs 32 of 50 after the insulin test, mainly symptoms of low blood sugar, 2 of them serious7. Treatment studies were small, and the one placebo-controlled growth trial was negative. In it, 126 short children with GH deficiency used a GHRP-2 nasal spray or a placebo spray twice daily for 48 weeks; height gain did not differ and IGF-1, the blood marker of GH action, did not change6. Earlier small studies without a placebo group reported faster growth on nasal or injected GHRP-2, also without a rise in IGF-12728. Infusions under the skin raised food intake: by 35.9% in 7 lean men, and by 10.2% on a low dose and 33.5% on a high dose in 19 lean and obese adults2021. In 10 older adults with low GH output, a continuous infusion under the skin for 30 days raised GH pulses and IGF-1 throughout29. In critically ill adults, a 21-hour infusion raised GH 4- to 6-fold and IGF-1 by 61% within 24 hours30. Over 5 days in critically ill men, GHRP-2 alone restored GH output and normalized IGF-1 but did not lower urea production, a marker of protein breakdown; combinations with the thyroid-stimulating hormone TRH did31. We found no trial of GHRP-2 for muscle gain, fat loss, recovery or anti-aging. The closest is a chart review of 105 men on testosterone who wanted more lean mass and less fat and were prescribed a blend of GHRP-2, GHRP-6 and sermorelin. In the 14 who met strict criteria, IGF-1 rose from 159.5 to 239.0 ng/mL, and the abstract reports no body-composition results3. A 2026 review concluded that beyond diagnosis, ‘broader therapeutic use of GHRP-2 remains limited’4. We rate GHRP-2 B because controlled human trials with public results exist, but none tested the uses it is sold for.

Key human studies

StudyDesignPeopleDose and routeResult
Tanaka et al., Clin Pediatr Endocrinol 20146PubMed · DOI Double-blind, placebo-controlled trial in prepubertal short children with GH deficiency (81 boys, 45 girls): placebo 44, low dose 41, high dose 41 126 Nasal spray twice daily (morning and evening) for 48 weeks: 50 or 100 µg per dose under 20 kg body weight, 100 or 200 µg per dose at 20 kg or more, or placebo Height SD score changed by +0.07 on placebo, +0.03 on the low dose and +0.02 on the high dose, with no significant difference, and IGF-1 did not change; 124 of 126 completed. The authors concluded that ‘growth cannot be promoted by a transient increase in endogenous GH secretion’6.
Kaken post-marketing survey (PMDA re-examination report), 20142Source Retrospective post-marketing survey at 19 sites in Japan, August 2006 to March 2012, of patients also tested with at least two other GH stimulation tests 503 One IV test dose in routine practice No side effects were recorded in 503 patients. Against doctors’ diagnoses made with at least two other tests, a GH peak of 9 ng/mL or less detected severe GH deficiency with 85.3% sensitivity and 88.5% specificity in 502 patients (249 children, 253 adults)2.
Chihara et al., Eur J Endocrinol 200726PubMed · DOI Diagnostic validation study: 77 healthy adults and 58 adults with severe GH deficiency (insulin tolerance test peak below 3 µg/L) 135 One 100 µg IV dose after an overnight fast; blood sampled over 2 hours GH peaked within 60 minutes in all subjects, averaging 84.6 µg/L in healthy adults vs 1.36 µg/L in patients. Responses were slightly lower in older and heavier people, without affecting the diagnosis. A 15 µg/L cut-off (9 µg/L with the recombinant GH standard) matched the insulin test’s 3 µg/L26.
Laferrère et al., Obesity (Silver Spring) 200621PubMed · DOI Double-blind, randomized, placebo-controlled study with three visits per person; 10 lean and 9 obese healthy adults 19 Infusion under the skin for 270 minutes: 1 µg/kg per hour (high dose), 0.1 µg/kg per hour (low dose) or placebo Food eaten at a buffet lunch rose by 10.2% on the low dose and 33.5% on the high dose vs placebo, and obesity did not change the effect. Appetite ratings before the meal were higher on the high dose, and GH rose with dose in everyone21.
Van den Berghe et al., Clin Endocrinol (Oxf) 200231PubMed · DOI Randomized study in men with prolonged critical illness, compared at baseline with 50 matched controls: placebo 7, GHRP-2 9, GHRP-2 plus TRH 9, GHRP-2 plus TRH plus GnRH pulses 8 33 5-day infusion of GHRP-2 at 1 µg/kg per hour, with TRH at 1 µg/kg per hour and GnRH at 0.1 µg/kg every 90 minutes in the combination groups (route not stated in the abstract) GHRP-2 alone reactivated GH secretion and normalized IGF-1, but did not lower urea production, a marker of protein breakdown; the combinations with TRH did. On day 5, blood lactate and white-cell counts were higher with GHRP-2 alone or with TRH31.
Sigalos et al., Am J Mens Health 20173PubMed · DOI Retrospective chart review with no control group: 105 men on testosterone who sought more lean mass and less fat; 14 met strict inclusion criteria 14 Given in the abstract as 100 µg of GHRP-6, GHRP-2 and SERM (sermorelin) three times daily, for a mean of 134 days; route not stated IGF-1 rose from 159.5 to 239.0 ng/mL (p < .0001); men also taking an aromatase inhibitor or tamoxifen had smaller rises. The abstract reports no body-composition, muscle or fat results3.

Doses studied

Doses below are what studies used or what a label says. They are not advice, and gray-market products may not contain what their label says.

In human studies

Japan’s approved test dose is 2 µg/kg for ages 4 to 17 (100 µg above 50 kg) and 100 µg for adults, injected slowly into a vein while fasting1. Studies in adults used 100 µg IV once for diagnosis26; 0.1 or 1 µg/kg per hour as a 270-minute infusion under the skin for appetite2021; a 1 µg/kg bolus then 1 µg/kg per hour for 21 hours, or 1 µg/kg per hour for 5 days, in critically ill patients3031; and 1 µg/kg per hour under the skin for 30 days in older adults29. Studies in children used a nasal spray of 50 to 200 µg twice daily for 48 weeks6, nasal doses of 5 to 15 µg/kg two or three times a day27, 0.3 to 3 µg/kg per day under the skin28 and 900 µg/kg by mouth twice daily for 12 months23. An anti-doping study gave one 10 mg oral dose37. These studies measured hormones, appetite, growth or detection, not muscle or fat4.

In animal studies

Pigs: single IV doses of 2 to 100 µg/kg raised GH in proportion to dose, and 30 µg/kg under the skin once daily for 30 days raised daily weight gain by 22% and feed efficiency by 21%, with a partly weaker GH response by day 1039. Rats and dogs: IV doses released GH in proportion to dose1.

What users report Anecdotal · not validated · not a recommendation

A 2026 medical review compiled bodybuilding-forum reports: 100 to 150 µg under the skin, 2 or 3 times a day4.

Half-life
About 25 to 41 minutes (0.42 to 0.69 hours) after a dose into a vein in healthy men1Elimination half-life after single IV doses of 0.3, 1.0 or 3.0 µg/kg in 18 healthy men. No metabolites were found in plasma after a 100 µg IV dose; by 24 hours about 2% of the dose appeared unchanged in urine and about 4% as metabolites, and excretion is thought to be mainly through bile, as in rats and dogs1. In 10 children given 1 µg/kg IV, the half-life was 0.55 hours and GH peaked at about 25 minutes (0.42 hours)38.
Routes
  • Intravenous injection (the approved one-dose test in Japan, and hospital studies)
  • Injection or infusion under the skin (research studies; the usual gray-market route)
  • Nasal spray (tested in children for growth)
  • By mouth (tested in children and in an anti-doping study)

Every dose studied for GHRP-2 (pralmorelin), with sources →

Quality and the gray market

What testing finds

Finnrick, a service that publishes lab results for peptide samples, listed no GHRP-2 tests and no rated vendors on 7 October 202617, so there are no independent data on what gray-market vials contain. FDA’s recall records name GHRP-2 in 30 compounded sermorelin products recalled by 9 US pharmacies between 21 May 2012 and 12 September 2019, all for lack of sterility assurance18. Doping-control chemists found glycine-extended GHRP-2, a look-alike with an extra amino acid, in products seized by Danish customs19. FDA notes that GHRP-2’s unnatural amino acid makes the substance harder to characterize8.

How it is sold

Sold online as ‘research use only’ powder, alone and in blends. On 7 October 2026 one US vendor listed GHRP-2 in 5 mg and 10 mg vials and in 5 blends with CJC-1295 or Mod GRF 1-29, ipamorelin, sermorelin or GHRP-6, under the statement ‘All products are for laboratory research use only’5. FDA’s 2024 CJC-1295 briefing also found research-use-only powders combining CJC-1295 with GHRP-235. Some doctors have prescribed it: a chart review describes 105 men on testosterone, seeking more lean mass and less fat, who were prescribed GHRP-2 with GHRP-6 and sermorelin three times daily3. FDA recall records show US compounding pharmacies making sermorelin blends with GHRP-2 from at least 2012 to 201918. In 2025 Health Canada warned about unauthorized injectable GHRP-2 seized from or sold by Canada Peptide14.

Side effects and risks

  • Unknown long-term safety: the approved use is a single test dose, and a 2026 review found no long-term safety data14.
  • Hunger: infusions raised food intake by about a third in healthy adults2021, and 7 of 10 children taking it by mouth reported a significant increase in appetite in the first 6 months23.
  • Stress hormones: single IV doses raised ACTH and cortisol about as much as a standard CRH test, and raised prolactin22.
  • Serious reports cited by FDA: increased insulin needs, deaths of critically ill study subjects, infection and pancreatitis; FDA says causality has not been established8.
  • Immune reactions and impurities: FDA warns that injected or nasal GHRP-2 could provoke immune responses because of clumping and peptide impurities8.
  • Side effects listed on the Japanese label for the test dose: in 5% or more, a feeling of warmth (16.0%), stomach rumbling and a rise in white blood cells; in 0.1% to 5%, low blood pressure, nausea, sleepiness, sweating, thirst, hunger and tiredness; at unknown frequency, dizziness, headache, flushing and a raised liver enzyme (ALT)1.
  • Pregnancy: the Japanese label says not to give it to women who are or may be pregnant, and it passes into milk in rats1.
  • Pituitary tumors: the label warns that similar drugs given to people with pituitary adenomas have been reported to cause pituitary apoplexy (sudden bleeding or loss of blood supply in the gland), with vision problems, headache and vomiting1.
  • Contaminated or wrong products: compounded blends containing GHRP-2 were recalled for lack of sterility assurance, and seized products have held look-alike versions1819.
  • Legal and anti-doping risk: banned in sport at all times and detectable in urine for up to 47 hours after a nasal dose; in Australia, possession without a prescription is illegal131536.

Documented harms

  • 5 Feb 2014Japan’s regulator reported 2 patients with 5 serious side effects after the GHRP-2 test during the 8-year re-examination period, all of whom recovered: impaired consciousness, facial pallor, abdominal pain, sweating and raised blood pressure, one of each. The 3 events the label did not predict (impaired consciousness, pallor and raised blood pressure) occurred in one patient and resolved the same day. That patient had a pituitary tumor, adrenal insufficiency, ventricular fibrillation and high blood pressure and took several drugs; the reporting doctor suspected missed morning doses, including hydrocortisone, and Kaken linked the blood-pressure rise more to a skipped blood-pressure drug. Kaken said a link to GHRP-2 could not be ruled out, but other causes were possible2.
  • 10 Oct 2016Five US consumer reports to FDA’s adverse event system (FAERS), received from 10 October 2016 to 1 December 2016, involved compounded sermorelin products that also contained GHRP-2 and GHRP-6. A 64-year-old woman was hospitalized with acute pancreatitis, nausea and vomiting, and reported a problem with the product’s physical consistency. A 39-year-old man using a ‘sermorelin acetate/GHRP injectable kit’ reported pain, infection and a repeated surgical procedure and was hospitalized; both reports were marked life-threatening. Three women aged 43 to 59 reported hives, itching, a pustular rash, burning, pain or fever, and one flagged a product quality problem. FAERS reports are unverified and cannot show which product, if any, caused an event40.
  • 22 May 2019A Japanese physician’s report to FAERS, based on a 2019 conference abstract, describes a 28-year-old man with an acute liver disorder (coded as worsening fatty liver) after surgery for a non-functioning pituitary tumor; GHRP-2 and hydrocortisone were listed as suspect drugs. A report like this does not show that GHRP-2 caused the problem40.
  • 29 Sep 2023FDA placed injectable and nasal GHRP-2 in the 503B category of compounding substances that raise significant safety risks, citing reports of serious adverse events including increased insulin needs, deaths of critically ill study subjects, infection and pancreatitis, ‘though causality has not been established’8.

Questions people ask

Is GHRP-2 FDA approved?

No. No FDA-approved drug contains it, and by our reading FDA’s compounding rules do not let US pharmacies make it91011. Japan approved it in 2004, but only as a one-dose test for growth hormone deficiency12.

What is pralmorelin used for?

Pralmorelin is the official generic name of GHRP-2. In Japan, doctors inject one dose into a vein while the patient is fasting and measure growth hormone over the next hour to diagnose severe growth hormone deficiency1.

Does GHRP-2 increase appetite?

Yes, in studies. Seven lean men ate 35.9% more at a buffet after a 270-minute infusion than after saline, and lean and obese adults ate 10.2% more on a low dose and 33.5% more on a high dose2021.

Does GHRP-2 raise cortisol?

Yes. In healthy young adults, single IV doses raised the stress hormones ACTH and cortisol about as much as the standard CRH test22. Researchers have studied that effect as a test for adrenal failure caused by pituitary or hypothalamic disease41.

Does GHRP-2 make kids grow taller?

Not in the only placebo-controlled trial we found: 126 short children with growth hormone deficiency used a GHRP-2 nasal spray or a dummy spray for 48 weeks, and growth did not differ6. Smaller studies without a placebo group reported faster growth2728.

Is GHRP-2 banned in sports?

Yes. The 2026 and 2027 Prohibited Lists name ‘GHRP-2 (pralmorelin)’ as banned at all times1516, and labs have detected it or its breakdown products in urine for up to 47 hours after a dose3637.

Is GHRP-2 the same as pralmorelin?

Yes. Pralmorelin is its international nonproprietary name, KP-102 was Kaken’s development code, and the Japanese product contains pralmorelin hydrochloride725.

What is still unknown

  • Kaken’s 2004 dossier reports side effects in 74 of 227 people (32.6%) in pre-approval trials, plus lab-test changes in 13, while the 2014 re-examination report gives 86 of 227 (37.9%); the second figure may combine the two, but neither document says so.
  • We found no study that tested GHRP-2 under the skin in adults for muscle, fat, recovery or aging outcomes.
  • FDA has not said which reports of deaths, infection or pancreatitis it relied on, so their link to GHRP-2 cannot be judged.
  • Uncontrolled studies reported faster growth in children, but the one placebo-controlled trial found none; whether dose, route or patient selection explains the gap is unknown.
  • No independent purity or content testing of gray-market GHRP-2 has been published.
  • UK and EU status, and whether a USP or NF monograph exists for GHRP-2, were not verified.

Sources

  1. 1GHRP KAKEN100 Injection (注射用GHRP科研100): package insert, revised July 2025 (in Japanese) KEGG MEDICUS (JAPIC package insert data), Jul 2025. kegg.jp
  2. 2Re-examination report for GHRP KAKEN100 Injection (注射用GHRP科研100, pralmorelin hydrochloride) (in Japanese) Pharmaceuticals and Medical Devices Agency (PMDA), Japan, 5 Feb 2014. pmda.go.jp
  3. 3Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels American Journal of Men’s Health, Nov 2017. pubmed.ncbi.nlm.nih.gov
  4. 4The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration Frontiers in Endocrinology, 18 Jun 2026. frontiersin.org
  5. 5Core Peptides shop page sorted by popularity Core Peptides (vendor), accessed 7 Oct 2026. corepeptides.com (seller page, deliberately not linked)
  6. 6Increased Secretion of Endogenous GH after Treatment with an Intranasal GH-releasing Peptide-2 Spray Does Not Promote Growth in Short Children with GH Deficiency Clinical Pediatric Endocrinology, Oct 2014. pubmed.ncbi.nlm.nih.gov
  7. 7GHRP KAKEN100 Injection (注射用GHRP科研100): summary of application data, origin and development (in Japanese) Kaken Pharmaceutical (published by PMDA), 2004. pmda.go.jp
  8. 8Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration, 22 Apr 2026. fda.gov
  9. 9Drugs@FDA search for the active ingredient pralmorelin (openFDA drugsfda endpoint; no matches) U.S. Food and Drug Administration (openFDA), accessed 7 Oct 2026. api.fda.gov · data query
  10. 10Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 14 May 2026. fda.gov
  11. 11Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act U.S. Food and Drug Administration, 14 May 2026. fda.gov
  12. 12Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 21 Mar 2025. fda.gov
  13. 13Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327) Federal Register of Legislation, Australian Government, 28 Sep 2026. legislation.gov.au
  14. 14Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks (RA-77807) Health Canada, 1 Aug 2025. recalls-rappels.canada.ca
  15. 15World Anti-Doping Code International Standard: Prohibited List 2026 World Anti-Doping Agency, 24 Sep 2025. wada-ama.org
  16. 16World Anti-Doping Code International Standard: Prohibited List 2027 World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
  17. 17GHRP-2: safety testing results and vendor ratings (no published tests) Finnrick, accessed 7 Oct 2026. finnrick.com
  18. 18FDA drug recall (enforcement report) records naming GHRP, via the openFDA drug/enforcement API U.S. Food and Drug Administration (openFDA), 30 Sep 2026. api.fda.gov · data query
  19. 19Glycine-modified growth hormone secretagogues identified in seized doping material Drug Testing and Analysis, Feb 2019. pubmed.ncbi.nlm.nih.gov
  20. 20Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men The Journal of Clinical Endocrinology & Metabolism, Feb 2005. pubmed.ncbi.nlm.nih.gov
  21. 21Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake Obesity (Silver Spring), Jun 2006. pubmed.ncbi.nlm.nih.gov
  22. 22Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH Peptides, 1997. pubmed.ncbi.nlm.nih.gov
  23. 23Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth hormone deficient children Journal of Pediatric Endocrinology and Metabolism, Sep 2003. pubmed.ncbi.nlm.nih.gov
  24. 24Pralmorelin, PubChem compound summary (CID 6918245) PubChem, U.S. National Library of Medicine, accessed 7 Oct 2026. pubchem.ncbi.nlm.nih.gov
  25. 25KEGG DRUG: Pralmorelin dihydrochloride (D02040) KEGG, Kanehisa Laboratories, accessed 7 Oct 2026. kegg.jp
  26. 26A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency European Journal of Endocrinology, Jul 2007. pubmed.ncbi.nlm.nih.gov
  27. 27Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature Journal of Endocrinology, Oct 1997. pubmed.ncbi.nlm.nih.gov
  28. 28Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children The Journal of Clinical Endocrinology & Metabolism, Jul 1998. pubmed.ncbi.nlm.nih.gov
  29. 29Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion Endocrine, Feb 2001. pubmed.ncbi.nlm.nih.gov
  30. 30The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion The Journal of Clinical Endocrinology & Metabolism, Feb 1997. pubmed.ncbi.nlm.nih.gov
  31. 31The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone Clinical Endocrinology, May 2002. pubmed.ncbi.nlm.nih.gov
  32. 32Drugs@FDA search for active ingredients named GHRP (openFDA drugsfda endpoint; no matches) U.S. Food and Drug Administration (openFDA), accessed 7 Oct 2026. api.fda.gov · data query
  33. 3321 CFR Part 1308, Schedules of Controlled Substances (eCFR, as of 25 September 2026) Electronic Code of Federal Regulations (eCFR), 25 Sep 2026. ecfr.gov
  34. 34Import Alert 66-41: Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S. U.S. Food and Drug Administration, 1 Oct 2026. accessdata.fda.gov
  35. 35FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of December 4, 2024: CJC-1295-related bulk drug substances U.S. Food and Drug Administration, 15 Nov 2024. fda.gov
  36. 36Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin Drug Testing and Analysis, Oct 2015. pubmed.ncbi.nlm.nih.gov
  37. 37Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry Analytical and Bioanalytical Chemistry, Aug 2011. pubmed.ncbi.nlm.nih.gov
  38. 38Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children The Journal of Clinical Endocrinology & Metabolism, Apr 1998. pubmed.ncbi.nlm.nih.gov
  39. 39The effects of growth hormone-releasing peptide-2 (GHRP-2) on the release of growth hormone and growth performance in swine Domestic Animal Endocrinology, Apr 2000. pubmed.ncbi.nlm.nih.gov
  40. 40FDA Adverse Event Reporting System (FAERS) reports naming GHRP-2, GHRP-6 or hexarelin, retrieved via the openFDA drug/event API U.S. Food and Drug Administration (openFDA), 30 Jul 2026. api.fda.gov · data query
  41. 41Investigation of the clinical significance of the growth hormone-releasing peptide-2 test for the diagnosis of secondary adrenal failure Endocrine Journal, 30 Jun 2016. pubmed.ncbi.nlm.nih.gov

Not medical advice. This page reports what studies and regulators say; it does not recommend using any product. How we grade evidence · Report an error.